Stock listing
TASE:XTLB XTL Biopharmaceuticals Ltd. מניה
Home listing (TASE) of XTL Biopharmaceuticals Ltd.
Follow XTL Biopharmaceuticals Ltd. into a list and get an email when it puts out news.
Share price · TASE:XTLB
1.30 ILA (agorot) -0.10 (-7.1%)
Close on Nov 19, 2026
- Day range
- 1.30 – 1.30 ILA (agorot)Nov 19, 2026
- Volume
- 936,830 sharesNov 19, 2026
- Market cap
- 12.78M ILSAt the close on Nov 19, 2026 · price × 983.0M shares outstanding
- 52-week range
- 1.30 – 4.40 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- 13,292 ILSMedian day 458,672 shares · 8 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:XTLB · Home | 1.30 ILA (agorot) | -0.10 (-7.1%) | 936,830 | 1.30 | 1.30 | 1.30 | 1.40 | Close on Nov 19, 2026 |
| NASDAQ:XTLB | $1.37 USD | -0.11 (-7.4%) | 1,780 | $1.585 | $1.585 | $1.37 | $1.48 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:XTLB · ILA (agorot), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 1.30 | -0.10 | -7.1% | 1.30 | 1.30 | 1.30 | 936,830 | |
| 1.40 | +0.10 | +7.7% | 1.40 | 1.40 | 1.40 | 1,011,071 | |
| 1.30 | -0.10 | -7.1% | 1.40 | 1.40 | 1.30 | 1,661,665 | |
| 1.40 | +0.10 | +7.7% | 1.40 | 1.40 | 1.40 | 702,866 | |
| 1.30 | 0.00 | 0.0% | 1.30 | 1.30 | 1.30 | 1,000,001 | |
| 1.30 | 0.00 | 0.0% | 1.30 | 1.30 | 1.30 | 1,663,184 | |
| 1.30 | -0.10 | -7.1% | 1.30 | 1.30 | 1.30 | 0 | |
| 1.40 | 0.00 | 0.0% | 1.30 | 1.40 | 1.30 | 820,000 | |
| 1.40 | 0.00 | 0.0% | 1.40 | 1.40 | 1.40 | 374,284 | |
| 1.40 | 0.00 | 0.0% | 1.40 | 1.50 | 1.40 | 479,884 | |
| 1.40 | 0.00 | 0.0% | 1.40 | 1.40 | 1.40 | 1,748,687 | |
| 1.40 | 0.00 | 0.0% | 1.40 | 1.40 | 1.40 | 0 | |
| 1.40 | 0.00 | 0.0% | 1.40 | 1.40 | 1.40 | 200,000 | |
| 1.40 | 0.00 | 0.0% | 1.50 | 1.50 | 1.40 | 778,000 | |
| 1.40 | 0.00 | 0.0% | 1.40 | 1.50 | 1.40 | 458,200 | |
| 1.40 | -0.10 | -6.7% | 1.40 | 1.40 | 1.40 | 1,796,138 | |
| 1.50 | 0.00 | 0.0% | 1.50 | 1.50 | 1.50 | 21,000 | |
| 1.50 | +0.10 | +7.1% | 1.40 | 1.50 | 1.40 | 377,202 | |
| 1.40 | -0.10 | -6.7% | 1.50 | 1.60 | 1.40 | 3,159,216 | |
| 1.50 | 0.00 | 0.0% | 1.50 | 1.50 | 1.50 | 79,600 | |
| 1.50 | -0.10 | -6.3% | 1.60 | 1.60 | 1.50 | 103,766 | |
| 1.60 | +0.10 | +6.7% | 1.50 | 1.60 | 1.50 | 443,736 | |
| 1.50 | 0.00 | 0.0% | 1.50 | 1.50 | 1.50 | 340,500 | |
| 1.50 | -0.10 | -6.3% | 1.60 | 1.60 | 1.50 | 1,537,736 | |
| 1.60 | 0.00 | 0.0% | 1.60 | 1.60 | 1.60 | 56,073 | |
| 1.60 | 0.00 | 0.0% | 1.60 | 1.60 | 1.60 | 73 | |
| 1.60 | 0.00 | 0.0% | 1.60 | 1.60 | 1.60 | 225,000 | |
| 1.60 | +0.10 | +6.7% | 1.60 | 1.60 | 1.60 | 0 | |
| 1.50 | -0.10 | -6.3% | 1.60 | 1.70 | 1.50 | 1,285,548 | |
| 1.60 | -0.20 | -11.1% | 1.70 | 1.80 | 1.60 | 3,520,742 | |
| 1.80 | 0.00 | 0.0% | 1.80 | 1.80 | 1.70 | 2,228,534 | |
| 1.80 | 0.00 | 0.0% | 1.90 | 1.90 | 1.80 | 927,528 | |
| 1.80 | 0.00 | 0.0% | 1.80 | 1.90 | 1.80 | 776,000 | |
| 1.80 | -0.10 | -5.3% | 1.80 | 1.80 | 1.80 | 459,143 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 1.90 | 1.80 | 527 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 1.90 | 1.90 | 0 | |
| 1.90 | +0.10 | +5.6% | 1.80 | 2.00 | 1.80 | 120,000 | |
| 1.80 | 0.00 | 0.0% | 1.80 | 1.80 | 1.80 | 0 | |
| 1.80 | 0.00 | 0.0% | 1.80 | 1.90 | 1.80 | 625,625 | |
| 1.80 | -0.10 | -5.3% | 1.90 | 1.90 | 1.80 | 679,452 | |
| 1.90 | +0.10 | +5.6% | 1.90 | 1.90 | 1.90 | 252,631 | |
| 1.80 | 0.00 | 0.0% | 1.80 | 1.80 | 1.80 | 0 | |
| 1.80 | -0.10 | -5.3% | 1.80 | 1.80 | 1.80 | 119,048 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 1.90 | 1.90 | 0 | |
| 1.90 | +0.10 | +5.6% | 1.90 | 1.90 | 1.90 | 0 | |
| 1.80 | -0.10 | -5.3% | 1.90 | 1.90 | 1.80 | 255,855 | |
| 1.90 | +0.10 | +5.6% | 1.90 | 1.90 | 1.90 | 465,657 | |
| 1.80 | -0.10 | -5.3% | 1.90 | 1.90 | 1.80 | 631,533 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 2.00 | 1.90 | 32,000 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 2.00 | 1.80 | 683,470 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 1.90 | 1.90 | 368,420 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 1.90 | 1.90 | 158,095 | |
| 1.90 | 0.00 | 0.0% | 1.90 | 1.90 | 1.90 | 52,832 | |
| 1.90 | 0.00 | 0.0% | 2.00 | 2.00 | 1.90 | 1,240,183 | |
| 1.90 | -0.10 | -5.0% | 1.90 | 1.90 | 1.90 | 1,309,052 | |
| 2.00 | 0.00 | 0.0% | 2.00 | 2.00 | 1.90 | 538,500 | |
| 2.00 | 0.00 | 0.0% | 2.00 | 2.00 | 2.00 | 261,500 | |
| 2.00 | -0.10 | -4.8% | 2.10 | 2.10 | 2.00 | 588,800 | |
| 2.10 | +0.10 | +5.0% | 2.10 | 2.10 | 2.10 | 664,406 | |
| 2.00 | 0.00 | 0.0% | 2.10 | 2.10 | 2.00 | 9,613,664 |
Splits
1 split · TASE:XTLB · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation |
- Ticker
- TASE:XTLB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TASE
- Currency
- ILA
What changed lately
Latest news
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
Apr 29, 2026
Closed 2.60 (+36.8%) on Apr 29, 2026
XTL Biopharmaceuticals Announces ADS Ratio Change
Mar 20, 2026
Closed 2.00 (-4.8%) on Mar 23, 2026
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
Feb 27, 2026
Closed 2.00 (-9.1%) on Mar 2, 2026
XTL Update on Recent Developments
Jan 29, 2026
Closed 2.80 (+7.7%) on Jan 30, 2026
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
Jan 23, 2026
Closed 2.90 (-6.5%) on Jan 26, 2026
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Jan 13, 2026
Closed 2.70 (-22.9%) on Jan 14, 2026
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Jan 13, 2026
Closed 3.50 (+52.2%) on Jan 13, 2026
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Dec 24, 2025
Closed 2.60 (-3.7%) on Dec 25, 2025
XTL Biopharmaceuticals Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 8 in the last 12 months · 9 in all · newest Apr 29, 2026 · oldest 2025
- Decks
- 9 decks · latest Nov 8, 2018
Where XTL Biopharmaceuticals Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:XTLB · Home listing · This page | TASE | Israel | ILA |
| NASDAQ:XTLB | NASDAQ | United States | USD |
| BOATS:XTLB | BOATS | United States | USD |
| gettex:HHB0 | gettex | Germany | EUR |
| Munich:HHB0 | Munich | Germany | EUR |
| Frankfurt:HHB0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A41X7J | Lang & Schwarz | Germany | EUR |
| LS Exchange:A41X7J | LS Exchange | Germany | EUR |
| Stuttgart:HHB0 | Stuttgart | Germany | EUR |
Team and board
Officers
| Officer | Role |
|---|---|
| Doron Turgeman | Chief Executive Officer |
| Joshua Levine | Chief Executive Officer |
| Shlomo Shalev | Chief Executive Officer |
| Itay Weinstein | Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Shlomo Shalev | Chief Executive Officer |
| Dobroslav Melamed | Director |
| Doron Turgeman | Chief Executive Officer |
| Iris Shapira Yalon | Director |
| Jonathan Schapiro | Director |
| Ossi Hillel Fain | Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2018) | Investor deck | 13 slides | Nov 8, 2018 |
| Investor Presentation (January 2017) | Investor deck | 27 slides | January 2017 |
| Investor Presentation (November 2015) | Investor deck | 20 slides | November 2015 |
| Investor Presentation (September 2015) | Investor deck | 20 slides | Sep 10, 2015 |
| Investor Presentation (June 2015) | Investor deck | 28 slides | June 2015 |
| Investor Presentation (May 2015) | Investor deck | 25 slides | May 2015 |
| Investor Presentation (December 2014) | Investor deck | 26 slides | December 2014 |
| IPO Roadshow (September 2014) | IPO roadshow | 31 slides | Sep 26, 2014 |
| Investor Presentation (January 2014) | Investor deck | 48 slides | January 2014 |
Financings
| Raise | Date |
|---|---|
| Private placement Announced: up to US$2M Use of proceeds: Together with the NeuroNOS acquisition, to remedy the Nasdaq minimum stockholders' equity deficiency | Jan 29, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 451.0K | |||||||||
| Cost of revenue | 448.0K | |||||||||
| Gross profit | 3.00K | |||||||||
| Research and development | 98.0K | 31.0K | 30.0K | 30.0K | 38.0K | 35.0K | 38.0K | 43.0K | 443.0K | 578.0K |
| Operating income | -2.17M | -765.0K | -880.0K | -1.03M | -948.0K | -842.0K | -793.0K | -1.25M | -2.56M | -3.61M |
| Depreciation and amortization | 199.0K | 1.00K | 1.00K | 1.00K | 1.00K | 3.00K | 7.00K | |||
| EBITDA | -1.97M | -879.0K | -1.03M | -947.0K | -1.25M | -2.56M | -3.60M | |||
| Interest expense | 28.0K | 1.56M | 21.0K | 2.19M | 603.0K | 35.0K | 337.0K | 7.00K | 15.0K | |
| Income before tax | -1.16M | -1.78M | -1.35M | |||||||
| Income tax | -130.0K | |||||||||
| Net income | -1.03M | -1.78M | -1.35M | 435.0K | -2.95M | -763.0K | 3.63M | -781.0K | -2.54M | 2.00K |
| Earnings per share, basic | -0.00 | -0.00 | -0.00 | 0.00 | -0.01 | -0.00 | 0.01 | -0.00 | -0.01 | |
| Earnings per share, diluted | -0.00 | -0.00 | -0.00 | 0.00 | -0.01 | -0.00 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 371.0K | 1.40M | 2.09M | 2.97M | 3.63M | 4.46M | 3.25M | 3.29M | 2.02M | 3.82M |
| Short-term investments | 1.63M | 3.16M | 2.41M | |||||||
| Receivables | 99.0K | |||||||||
| Current assets | 1.34M | 2.05M | 3.81M | 6.24M | 6.12M | 6.83M | 8.20M | 6.21M | 2.75M | |
| Property, plant and equipment | 187.0K | 10.0K | ||||||||
| Goodwill | 3.19M | |||||||||
| Total assets | 8.55M | 2.43M | 4.19M | 6.62M | 6.50M | 7.21M | 8.57M | 6.59M | 3.02M | |
| Accounts payable | 790.0K | 206.0K | 187.0K | 231.0K | 254.0K | 232.0K | 253.0K | 300.0K | 17.0K | |
| Current liabilities | 2.21M | 206.0K | 300.0K | 330.0K | ||||||
| Total debt | 138.0K | |||||||||
| Shareholders' equity | 5.43M | 2.22M | 4.00M | 5.33M | 3.61M | 6.51M | 7.27M | 3.62M | 2.69M | 4.89M |
| Shares outstanding | 881.4M | 544.9M | 544.9M | 544.9M | 514.2M | 514.2M | 514.2M | 514.2M | 274.2M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1.62M | -707.0K | -901.0K | -1.05M | -850.0K | -908.0K | -816.0K | -1.13M | -1.73M | -1.86M |
| Capital spending | -54.0K | -1.00K | -2.00K | -2.00K | -2.00K | |||||
| Free cash flow | -1.67M | -851.0K | -910.0K | -1.73M | -1.86M | |||||
| Cash from investing | -844.0K | 41.0K | 36.0K | 8.00K | 32.0K | 2.11M | 778.0K | -2.50M | -66.0K | -110.0K |
| Cash from financing | 1.45M | 385.0K | 4.89M | 3.58M | ||||||
| Change in cash | -1.01M | -666.0K | -865.0K | -656.0K | -818.0K | 1.20M | -38.0K | 1.27M | -1.80M | 1.61M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 14, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 21, 2026 | Current report | SEC |
| 20-F · Annual report | Jun 30, 2026 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 22, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 22, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 548 filings. Open Filings
Cap table
Built by 6ix from XTL Biopharmaceuticals Ltd.’s releases · as of Jan 29, 2026
- Common shares
- 982,985,356
- Fully diluted
- 982,985,356
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 982,985,356 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 982,985,356 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kenneth J Zuerblis Other companies: Stemline Therapeutics Inc (Director · Jan 28, 2013 – Jun 10, 2020 · Past); Savient Pharmaceuticals Inc (EVP, Chief Financial Officer · Sep 12, 2011 – Feb 1, 2012 · Past); Immunomedics Inc (Director · Feb 9, 2010 – Dec 7, 2011 · Past) | Director · Oct 10, 2008 – Oct 10, 2008 · Past |
| William James Kennedy Other companies: TG Therapeutics, Inc. (Director · Apr 16, 2012 – Jun 17, 2020 · Past) | Director · Nov 4, 2008 – Nov 4, 2008 · Past |
| Dobroslav Melamed | Director · Since at least Nov 6, 2026 |
| Doron Turgeman | Chief Executive Officer · Since at least Nov 6, 2026 |
| Fain Osnat Hillel | Director · Since at least Mar 18, 2026 |
| Iris Shapira Yalon | Director · Since at least Nov 6, 2026 |
| Itay Weinstein | Chief Financial Officer · Since at least Nov 6, 2026 |
| Jonathan Schapiro | Director · Since at least Nov 6, 2026 |
| Joshua Levine | Chief Executive Officer · Since at least Nov 6, 2026 |
| Noam Band | Chief Executive Officer · Apr 7, 2025 – Nov 6, 2026 · Past |
All 14 people
| Person | Seat |
|---|---|
| Ossi Hillel Fain | Director · Since at least Nov 6, 2026 |
| Samuel Rudman | Director · Oct 10, 2008 – Oct 10, 2008 · Past |
| Shlomo Shalev | Chief Executive Officer · Since at least Apr 7, 2025 |
| William Kessler | Director of Finance · Aug 21, 2007 – Aug 21, 2007 · Past |
Log in to ask 6ix AI your own questions about XTL Biopharmaceuticals Ltd.